LANXESS launches Rely+On Medero powder disinfectant for medical sector

LANXESS is launching Rely+On Medero, a powder disinfectant for medical devices and surfaces based on potassium monopersulfate (Oxone) and in-situ generated active chlorine. The product is approved as a Class IIa medical device disinfectant under the EU Medical Device Regulation and is offered in 20- or 40-gram sachets and in 1 kilo or 5 kilo units. LANXESS aims to start distribution in many countries across Europe, Asia and South America.

Key facts

Market context

Potassium monopersulfate, sold commercially as Oxone, is a triple-salt oxidant used in water treatment, pulp and paper bleaching, surface cleaning, and as a reagent in organic synthesis. Its ability to release active oxygen makes it useful where chlorine-based chemistry is less suitable. Demand for disinfectants of this kind is driven mainly by hospitals, clinics, and other healthcare facilities, where infection control rules require validated products for medical devices and surfaces. Regulatory classification matters greatly in this segment: products sold as medical device disinfectants must meet specific conformity requirements, which limits competition to suppliers able to meet them. Powder formats in small sachets can simplify storage and transport compared with ready-to-use liquids, and they allow dosing at the point of use. Any move by a major specialty chemicals producer into this niche tends to affect distributors and smaller disinfectant formulators competing for hospital contracts, and it can shift buyer attention toward suppliers with established regulatory approvals.

Source: official release on lanxess.com. Summary and context written by Market Krystal.